Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "The-Drug-Controller-General-of-India"

27 News Found

DCGI approves Themis Medicare's Viralex for Covid-19 treatment
News | March 03, 2022

DCGI approves Themis Medicare's Viralex for Covid-19 treatment

Viralex is an immunomodulatory agent with broad-spectrum antiviral properties. It enhances both innate & adaptive immunity and strengthens the body's defence response to viral infections


Lupin launches Molnulup to treat Covid-19
News | January 07, 2022

Lupin launches Molnulup to treat Covid-19

The drug is priced at Rs 2000 for a course of 40 tablets


Bharat Biotech's intranasal vaccine Phase 3 trials gets approval
News | January 05, 2022

Bharat Biotech's intranasal vaccine Phase 3 trials gets approval

It has also been granted permission to conduct trials for booster dose


Emcure to launch oral Covid-19 drug soon
Drug Approval | January 03, 2022

Emcure to launch oral Covid-19 drug soon

A toll-free helpline to be set up to help doctors and patients


Cipla receives EUA for Cipmolnu
Drug Approval | December 28, 2021

Cipla receives EUA for Cipmolnu

The Subject Expert Committee (SEC), on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO) on Monday recommended granting permission to manufacture and market anti-Covid pill molnupiravir for restricted emergency use


Booster dose  for those above 40
News | December 03, 2021

Booster dose for those above 40

The recommendation was made by the Indian SARS-CoV-2 Genomics Sequencing Consortium (INSACOG), a network of national testing labs set up by the government to monitor genomic variations of Covid-19


Serum seeks DCGI approval for booster dose in India
News | December 02, 2021

Serum seeks DCGI approval for booster dose in India

The UK’s Medicine and Healthcare products Regulatory Agency has already approved the booster dose of AstraZenenca’s Covid-19 vaccine, which is administered in India


Zydus Cadila submits NDA to Drug Controller General of India for Chronic Kidney Disease
Biotech | November 23, 2021

Zydus Cadila submits NDA to Drug Controller General of India for Chronic Kidney Disease

The NDA for Desidustat is based on positive data from the DREAM-ND and DREAM-D Phase 3 trials in patients with Chronic Kidney Disease (CKD) Not on Dialysis and Dialysis


Sun Pharma to introduce molnupiravir in India
Drug Approval | November 12, 2021

Sun Pharma to introduce molnupiravir in India

The Drug Controller General of India (DCGI), is reviewing clinical data of molnupiravir for the treatment of Covid-19 in adults in India


Cadila Healthcare receives permission to conduct Phase III trials for two-dose ZyCoV-D
News | October 06, 2021

Cadila Healthcare receives permission to conduct Phase III trials for two-dose ZyCoV-D

The company has already received the emergency use authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D to be administered in three doses on August 20